"Safety assessment of dexamethasone administration during pregnancy: A Cross-Sectional study"
DOI:
https://doi.org/10.54361/LJMR.19.2.49Keywords:
dexamethasone, pregnancy, side effectsAbstract
Background: Dexamethasone, a glucocorticoid drug, is used to treat a variety of conditions, including rheumatism, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, eye pain after eye surgery, superior vena cava syndrome (a side effect of some types of cancer), and tuberculosis in conjunction with steroids.Aim of the study: The present study aims to evaluate the extent of the safe use of the drug dexamethasone, its effectiveness, and its side effects on pregnant women. Material and Method: 484 participants were surveyed using a paper questionnaire that included several information about social and drug side effects. The data were analyzed statistically by using SPSS v. 27. Results: our results suggest that there is no statistically significant association between taking dexamethasone during pregnancy and the occurrence of hypertension, diabetes, need for hospitalization, or depression and psychological pressure. However, there is a statistically significant association between taking dexamethasone and the awareness of lung acupuncture. Conclusion: Dexamethasone use during pregnancy is not substantially linked to an elevated risk of common pregnancy-related problems, such as gestational diabetes mellitus and hypertensive disorders of pregnancy, according to the study's findings. Hospitalization due to pregnancy, psychological anguish, or depression.
Downloads
References
1. Dexamethasone [oral route] – Side effects & dosage. Mayo Clinic. Updated 2024.
2. Bora RS, Chetterjee S. Dexamethasone. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
3. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006;(3):CD004454. doi:10.1002/14651858.CD004454.
4. Khandelwal M, Moore JJ. Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. Obstet Gynecol. 2010;116(2 Pt 1):210-214.
5. Verhaeghe J, Diderich K, Baschat A, et al. Safety of antenatal predniso[lo]ne and dexamethasone on fetal, neonatal, and childhood outcomes: a systematic review. J Clin Endocrinol Metab. 2023;108(7): e1-e15.
6. U.S. Food and Drug Administration [FDA]. Pregnancy and lactation labeling [drugs in pregnancy category C]. FDA Drug Safety Communication; 2024.
7. Therapeutic Goods Administration [TGA]. Australian categorisation system for prescribing medicines in pregnancy. Canberra: Australian Government Department of Health; Updated 2025.
8. Tripathi V, Kumar A, Sharma S. Maternal education and its impact on antenatal care utilization in urban settings: a cross-sectional study. J Matern Fetal Neonatal Med. 2022;35(4):755-762.
9. 9.Graham SW, Bakar A, Li Z. Socioeconomic disparities in the quality and frequency of antenatal care visits in middle-income countries. Int J Equity Health. 2021;20(1):150.
10. Kolderup SC, Tuthill D. Advanced maternal age and adverse pregnancy outcomes: a systematic review and meta-analysis. Obstet Gynecol Surv. 2019;74(11):685-693.
11. Betrán AP, Merialdi M, Lauer JA, et al. Rates of caesarean section: analysis of global, regional and national estimates. Paediatr Perinat Epidemiol. 2007;21(2):98-113.
12. Taggart MK, Li R, Clark E. Management of chronic and gestational hypertension in pregnancy. J Obstet Gynaecol Can. 2020;42(8):998-1008.
13. Yonkers KLZ, Badr H, Rood B. Risk factors for perinatal depression: a synthesis of recent literature. Am J Psychiatry. 2021;178(9):834-845.
14. Smith CA, Smith Z, Zhang J. Acupuncture for common health issues during pregnancy: a review of the evidence. Evid Based Complement Alternat Med. 2018; 2018:7831093.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Suhila Alhadi Atwier, Hager Tahir Ali , Entesar Rajeb Knaz , Asmahan. A.Abukhdir , Rabab Almabrok Alhade. (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
